Evidence map›Paper›PMID 39596451›Full record

ArticleInternational journal of molecular sciences2024

Development of LAT1-Selective Nuclear Medicine Therapeutics Using Astatine-211.

Kazuko Kaneda-Nakashima, Yoshifumi Shirakami, Kentaro Hisada, Sifan Feng, Yuichiro Kadonaga, Kazuhiro Ooe, Tadashi Watabe, Yoshiyuki Manabe, Atsushi Shimoyama, Masashi Murakami and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. First-in-human evaluation of [European journal of nuclear medicine and molecular imaging · 2026
    Article
  2. LAT1-Targeted Alpha Therapy UsingInternational journal of molecular sciences · 2025
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Kazuko Kaneda-NakashimaRadiation Biological Chemistry, MS-CORE, FRC, Graduate School of Science, Osaka University, 1-1 Machikaneyama-cho, Toyonaka, Osaka 560-0043, Japan.ORCID 0000-0001-6657-5059
Yoshifumi ShirakamiInstitute for Radiation Sciences, Osaka University, 2-4 Yamadaoka, Suita, Osaka 565-0871, Japan.ORCID 0000-0003-2352-9057
Kentaro HisadaRadiation Biological Chemistry, MS-CORE, FRC, Graduate School of Science, Osaka University, 1-1 Machikaneyama-cho, Toyonaka, Osaka 560-0043, Japan.
Sifan FengRadiation Biological Chemistry, MS-CORE, FRC, Graduate School of Science, Osaka University, 1-1 Machikaneyama-cho, Toyonaka, Osaka 560-0043, Japan.
Yuichiro KadonagaInstitute for Radiation Sciences, Osaka University, 2-4 Yamadaoka, Suita, Osaka 565-0871, Japan.
Kazuhiro OoeInstitute for Radiation Sciences, Osaka University, 2-4 Yamadaoka, Suita, Osaka 565-0871, Japan.ORCID 0000-0002-8560-027X
Tadashi WatabeDepartment of Radiology, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan.ORCID 0000-0001-8658-2395
Yoshiyuki ManabeInstitute for Radiation Sciences, Osaka University, 2-4 Yamadaoka, Suita, Osaka 565-0871, Japan.ORCID 0000-0002-5515-3923
Atsushi ShimoyamaInstitute for Radiation Sciences, Osaka University, 2-4 Yamadaoka, Suita, Osaka 565-0871, Japan.ORCID 0000-0003-1910-0450
Masashi MurakamiInstitute for Radiation Sciences, Osaka University, 2-4 Yamadaoka, Suita, Osaka 565-0871, Japan.ORCID 0000-0001-7936-2263
Atsushi ToyoshimaInstitute for Radiation Sciences, Osaka University, 2-4 Yamadaoka, Suita, Osaka 565-0871, Japan.
Hiromitsu HabaNishina Center, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan.
Yoshikatsu KanaiPremium Research Institute for Human Metaverse Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan.
Koichi FukaseInstitute for Radiation Sciences, Osaka University, 2-4 Yamadaoka, Suita, Osaka 565-0871, Japan.ORCID 0000-0001-8844-0710

Funding

Foundation for the Promotion of Cancer Research General Research Proposal A 2022Japan Agency for Medical Research and Development JP23ym0126809JSPS KAKENHI JP18K07323JSPS KAKENHI JP21K07619Sumitomo Foundation Grant for Basic Science Research Projects
6 · The paper itself

Abstract

We investigated nuclear medicine therapeutics targeting the L-type amino acid transporter 1 (LAT1). We previously reported that a nuclear medicine therapeutic drug using astatine 211 (

Indexed as

AstatineLarge Neutral Amino Acid-Transporter 1AnimalsCell Line, TumorHumansNuclear MedicineRadiopharmaceuticalsAstatineAstatine-211Large Neutral Amino Acid-Transporter 1Radiopharmaceuticalsamino acidastatine-211cancer therapyLAT1nuclear medicine

Identifiers

PMID39596451
PMCPMC11594329

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.